Facial reconstruction

Search LJMU Research Online

Browse Repository | Browse E-Theses

The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth

Hanson, K, Robinson, SR, Al-Yousuf, K, Hendry, AE, Sexton, DW, Sherwood, V and Wheeler, GN (2017) The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth. Oncotarget, 9 (3). ISSN 1949-2553

[img]
Preview
Text
The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth.pdf - Published Version
Available under License Creative Commons Attribution.

Download (3MB) | Preview

Abstract

Cutaneous melanoma, which develops from the pigment producing cells called melanocytes, is the most deadly form of skin cancer. Unlike the majority of other cancers, the incidence rates of melanoma are still on the rise and the treatment options currently available are being hindered by resistance, limited response rates and adverse toxicity. We have previously shown that an FDA approved drug leflunomide, used for rheumatoid arthritis (RA), also holds potential therapeutic value in treating melanoma especially if used in combination with the mutant BRAF inhibitor, vemurafenib. We have further characterized the function of leflunomide and show that the drug reduces the number of viable cells in both wild-type and BRAFV600E mutant melanoma cell lines. Further experiments have revealed leflunomide reduces cell proliferation and causes cells to arrest in G1 of the cell cycle. Cell death assays show leflunomide causes apoptosis at treatment concentrations of 25 and 50 μM. To determine if leflunomide could be used combinatorialy with other anti-melanoma drugs, it was tested in combination with the MEK inhibitor, selumetinib. This combination showed a synergistic effect in the cell lines tested. This drug combination led to an enhanced decrease in tumor size when tested in vivo compared to either drug alone, demonstrating its potential as a novel combinatorial therapy for melanoma.

Item Type: Article
Uncontrolled Keywords: Science & Technology; Life Sciences & Biomedicine; Oncology; Cell Biology; melanoma; leflunomide; selumetinib; MEK inhibitors; combinatorial therapy; METASTATIC MELANOMA; TRANSCRIPTIONAL ELONGATION; TARGETED THERAPIES; NEURAL CREST; BRAF; CANCER; RESISTANCE; CELLS; MITOCHONDRIA; VEMURAFENIB
Subjects: R Medicine > RM Therapeutics. Pharmacology
Divisions: Pharmacy & Biomolecular Sciences
Publisher: Impact Journals
Related URLs:
Date Deposited: 19 Feb 2018 11:22
Last Modified: 19 Feb 2018 11:22
DOI or Identification number: 10.18632/oncotarget.23378
URI: http://researchonline.ljmu.ac.uk/id/eprint/8054

Actions (login required)

View Item View Item